Immunotherapy for Management of Stage 3B NSCLC – OncLive
OncLive |
Immunotherapy for Management of Stage 3B NSCLC
OncLive Everett Vokes, MD: At this point, we should move on and talk a little bit about earlier stage disease and how therapies are developing. This year, at The European Society for Medical Oncology (ESMO) 2017 Congress, in particular, we've received new … |
